Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients (2006/25)

June 1, 2012 updated by: Assistance Publique Hopitaux De Marseille

Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients

This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Candidates will be screened with medical history and blood tests.Then, 2 groups of 20 patients (with or without CMV reactivation) matched for CMV status will be compared for their immune system against CMV.

Study Type

Interventional

Enrollment (Actual)

29

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Marseille, France, 13009
        • Hôpital de Sainte Marguerite- Service de Réanimation Médicale

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age more than 18-year-old
  • Informed consent

Exclusion Criteria:

  • minors,
  • pregnant or lactating women,
  • adults under guardianship,
  • immunosuppression at the entrance to resuscitation,
  • AIDS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
Infection to CMV
Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Sampling of blood
OTHER: 2
Group "control CMV"
Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Sampling of blood

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Bring to light the quantitative and qualitative immunological modifications of the present cells NK before the arisen of an infection to CMV
Time Frame: 24 months
24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Bring to light the quantitative and qualitative immunological modifications of cells NK in the consequences of an infectious shock
Time Frame: 24 months
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique Hopitaux De Marseille

Investigators

  • Principal Investigator: Jean-Marie FOREL, MD, Assistance Publique des Hôpitaux de Marseille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2008

Primary Completion (ACTUAL)

January 1, 2011

Study Completion (ACTUAL)

August 1, 2011

Study Registration Dates

First Submitted

June 13, 2008

First Submitted That Met QC Criteria

June 17, 2008

First Posted (ESTIMATE)

June 18, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

June 4, 2012

Last Update Submitted That Met QC Criteria

June 1, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2007-A01197-46

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cytomegalovirus Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe